Deals
Gilead to Boost Stake in Galapagos as Part of $5.1 Billion Deal
- Deal worth $5.1 billion to help Belgian firm’s research push
- Galapagos founder sees boost to entire European biotech sector
This article is for subscribers only.
Gilead Sciences Inc.’s $5.1 billion investment in Galapagos NV propelled the Belgian biotechnology company’s stock to a record while sending a positive signal to the rest of the sector in Europe, where the industry has lagged the U.S.
The amount Gilead is investing tops the $4.7 billion that has flowed to European pharma and biotech companies this year in mergers, acquisitions and share investments. It compares with a whopping $240 billion in the U.S., a number that was boosted by a handful of mega deals, Bloomberg data shows.